Try our Advanced Search for more refined results

Genentech, Inc. et al v. Amgen Inc.

  1. August 03, 2018

    PTAB Shoots Down Pfizer's Bid To Review Avastin Patent

    The Patent Trial and Appeal Board has turned down Pfizer Inc.'s challenge to a patent covering Genentech Inc.'s blockbuster cancer treatment Avastin, finding the challenger couldn't prove the patent shouldn't have been issued.

  2. January 03, 2018

    Amgen Says It Didn't Mislead On Biosimilar Marketing Date

    Amgen Inc. in a brief unsealed Tuesday urged a Delaware federal judge to dismiss a claim by Genentech Inc. that it had breached a "binding" representation that it would market its biosimilar of cancer drug Avastin at a certain date, arguing the biotechnology rival "mischaracterize[d]" Amgen's statement.

  3. October 27, 2017

    Amgen 'Completely Ignoring' Biosimilar Law, Genentech Says

    Amgen Inc. has been "completely ignoring" its information-disclosure obligations under the federal biosimilars law in order to shield its biosimilar of blockbuster cancer drug Avastin, Genentech Inc. claims in a newly unsealed complaint.